Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
370.00Today’s High
384.3052W low
222.0052W High
430.00Open Price
370.00Prev. Close
312.9500Volume
94277.00Value
36065666.35Fundamentals
Market Cap
511.40
Price to Earnings
18.00
Price to Book Value
1.00
Dividend Yield
0.00
PE to Growth
2.50
Op Revenue TTM
601.45
Net Profit TTM
28.48
Cash From Operating Activity
37.28
Return on Equity %
5.84
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
58.1
Week
55.2
Month
45.8
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
378.93
PIVOT
First Resistance
387.92
Second Resistance
393.28
Third Resistance
402.27
First Support
373.57
Second Support
364.58
Third Support
359.22
Relative Strength Index
65.91
Money Flow Index
55.18
MACD
12.93
MACD Signal
13.37
Average True Range
15.22
Average Directional Index
29.74
Rate of Change (21)
25.82
Rate of Change (125)
-7.29
Commodity Channel Index
59.9
Williams %R
-25.4
BETA
1 Month
-0.17
3 Month
0.51
1 Year
0.46
3 Year
0.1
PRICE CHANGE ANALYSIS
↑ 6.69%
1 Week
Low
High
357.2
384.3
↑ 25.82%
1 Month
Low
High
300
395
↑ 10.84%
3 Months
Low
High
285
395
↓ -7.33%
6 Months
Low
High
281.1
429.4
↑ 46.88%
1 Year
Low
High
222
430
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 179.07 | 133.65 | 173.12 | 100.69 | 151.77 | 113.20 | 126.52 | 156.34 | 130.72 | 118.51 | 195.61 | |
| Operating Expenses Qtr | 153.88 | 118.23 | 157.06 | 85.16 | 127.50 | 102.37 | 109.58 | 136.68 | 120.95 | 103.21 | 164.71 | |
| Operating Profit Qtr | 21.29 | 13.00 | 13.13 | 13.47 | 21.03 | 7.08 | 15.17 | 18.25 | 7.30 | 14.23 | 27.93 | |
| EBIDT Qtr Cr | 25.20 | 15.42 | 16.06 | 15.53 | 24.27 | 10.83 | 16.94 | 19.66 | 9.77 | 15.30 | 30.90 | |
| Depreciation Qtr | 5.72 | 6.30 | 6.21 | 7.32 | 8.06 | 6.97 | 8.77 | 7.57 | 7.36 | 8.40 | 8.46 | |
| Net Profit Qtr | 12.52 | 8.19 | 5.45 | 4.34 | 7.54 | 2.61 | 7.73 | 11.09 | 2.42 | 7.85 | 24.13 | |
| Basic EPS Qtr | 9.36 | 6.13 | 4.07 | 3.25 | 5.64 | 1.95 | 5.78 | 8.30 | 1.81 | 5.87 | 18.05 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 586.53 | 547.84 | 583.61 | 532.39 | 323.81 | |
| Operating Expenses Annual Cr | 514.33 | 476.14 | 506.36 | 467.76 | 277.16 | |
| Operating Profit Annual | 60.88 | 61.53 | 68.82 | 46.86 | 43.07 | |
| Operating Profit Margin Annual % | 10.38 | 11.23 | 11.79 | 8.80 | 13.30 | |
| Total Expenses Annual Cr | 539.88 | 507.51 | 538.94 | 514.77 | 321.26 | |
| EBIDT Annual Cr | 72.20 | 71.70 | 77.25 | 64.62 | 46.65 | |
| EBIDT Annual margin % | 12.31 | 13.09 | 13.24 | 12.14 | 14.41 | |
| Depreciation | 25.55 | 31.37 | 32.58 | 34.28 | 31.05 | |
| PAT Before ExtraOrdinary Items Annual Cr | 30.50 | 28.96 | 48.99 | 54.27 | -8.23 | |
| Net Profit Annual | 30.50 | 28.96 | 48.99 | 54.27 | -8.23 | |
| Basic EPS Annual | 22.82 | 21.67 | 37.12 | 43.97 | -6.67 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 508.59 | 478.05 | 449.41 | 400.18 | 332.25 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 59.86 | 58.17 | 46.63 | 58.81 | 96.03 | |
| Total Current Liabilities Annual Cr | 72.81 | 72.67 | 82.61 | 87.82 | 209.93 | |
| Total Capital Plus Liabilities Annual Cr | 641.26 | 608.89 | 578.66 | 546.81 | 638.21 | |
| Fixed Assets Annual | 223.84 | 225.77 | 249.90 | 269.31 | 296.10 | |
| Total Non Current Assets Annual | 280.26 | 290.57 | 314.25 | 335.51 | 360.33 | |
| Total Current Assets Annual | 361.00 | 318.32 | 264.41 | 211.30 | 277.89 | |
| Total Assets Annual | 641.26 | 608.89 | 578.66 | 546.81 | 638.21 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 32.91 | 10.83 | 1.29 | 0.21 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 35.38 | 28.05 | 40.90 | 132.67 | 77.15 | |
| Cash from Investing Activity Annual | -6.95 | -50.81 | -16.65 | 55.65 | -4.64 | |
| Cash from Financing Annual Activity | 0.00 | 0.00 | -9.13 | -161.88 | -72.35 | |
| Net Cash Flow Annual | - | -22.76 | 15.12 | 26.45 | 0.16 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 380.40 | 357.63 | 336.21 | 324.24 | 269.20 | |
| ROE Annual % | 5.99 | 6.05 | 10.90 | 13.56 | -2.47 | |
| ROCE Annual % | 8.20 | 7.52 | 9.00 | 6.61 | 3.64 | |
| Total Debt to Total Equity Annual | 0.08 | 0.08 | 0.09 | 0.12 | 0.46 | |
| EBDIT Annual Margin % | 12.55 | 13.33 | 13.43 | 12.55 | 14.56 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 199.08 | 145.77 | 170.77 | 97.41 | 159.05 | 120.71 | 141.68 | 144.52 | 144.18 | 125.56 | 205.45 | |
| Operating Expenses Qtr | 175.68 | 131.38 | 149.93 | 84.75 | 131.03 | 108.80 | 126.92 | 128.57 | 136.39 | 111.91 | 175.26 | |
| Operating Profit Qtr | 19.48 | 12.04 | 17.79 | 10.40 | 24.61 | 8.10 | 12.97 | 14.51 | 5.54 | 12.44 | 27.30 | |
| EBIDT Qtr Cr | 23.40 | 14.39 | 20.84 | 12.66 | 28.02 | 11.91 | 14.76 | 15.95 | 7.79 | 13.65 | 30.19 | |
| Depreciation Qtr | 5.91 | 6.54 | 6.44 | 7.55 | 8.29 | 7.22 | 8.99 | 7.80 | 7.56 | 8.64 | 8.71 | |
| Net Profit Qtr | 10.51 | 6.85 | 9.94 | 1.18 | 11.06 | 3.29 | 5.33 | 6.89 | 0.23 | 5.65 | 23.15 | |
| Basic EPS Qtr | 7.86 | 5.13 | 7.44 | 0.88 | 8.27 | 2.46 | 3.99 | 5.16 | 0.17 | 4.22 | 17.32 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 613.03 | 565.83 | 606.96 | 567.75 | 344.64 | |
| Operating Expenses Annual Cr | 541.86 | 495.31 | 536.54 | 494.35 | 298.52 | |
| Operating Profit Annual | 59.59 | 60.20 | 62.11 | 53.78 | 40.82 | |
| Operating Profit Margin Annual % | 9.72 | 10.64 | 10.23 | 9.47 | 11.84 | |
| Total Expenses Annual Cr | 568.39 | 527.90 | 570.55 | 542.64 | 343.87 | |
| EBIDT Annual Cr | 71.17 | 70.52 | 70.42 | 73.41 | 46.13 | |
| EBIDT Annual margin % | 11.61 | 12.46 | 11.60 | 12.93 | 13.38 | |
| Depreciation | 26.44 | 32.30 | 33.53 | 35.28 | 32.01 | |
| PAT Before ExtraOrdinary Items Annual Cr | 28.49 | 26.57 | 40.72 | 61.77 | -10.00 | |
| Net Profit Annual | 28.49 | 26.57 | 40.72 | 61.77 | -10.00 | |
| Basic EPS Annual | 21.31 | 19.88 | 30.86 | 50.04 | -8.10 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 487.55 | 460.34 | 440.45 | 400.28 | 323.37 | |
| Minority Interest Liability Annual Cr | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non Current Liabilities Annual Cr | 59.86 | 58.17 | 46.63 | 58.12 | 95.82 | |
| Total Current Liabilities Annual Cr | 79.42 | 82.57 | 92.74 | 97.45 | 218.53 | |
| Total Capital Plus Liabilities Annual Cr | 626.83 | 601.08 | 579.82 | 555.85 | 637.72 | |
| Fixed Assets Annual | 239.61 | 242.06 | 266.17 | 286.79 | 314.00 | |
| Total Non Current Assets Annual | 267.30 | 278.12 | 301.78 | 324.26 | 349.77 | |
| Total Current Assets Annual | 359.53 | 322.96 | 278.04 | 231.60 | 287.95 | |
| Total Assets Annual | 626.83 | 601.08 | 579.82 | 555.85 | 637.72 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 32.91 | 10.83 | 1.29 | 0.21 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 37.28 | 36.63 | 41.00 | 132.61 | 77.01 | |
| Cash from Investing Activity Annual | -7.21 | -50.83 | -16.63 | 55.72 | -4.75 | |
| Cash from Financing Annual Activity | -1.08 | -0.57 | -9.48 | -162.24 | -73.00 | |
| Net Cash Flow Annual | 28.99 | -14.77 | 14.90 | 26.09 | -0.74 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 364.66 | 344.38 | 329.50 | 324.33 | 262.01 | |
| ROE Annual % | 5.84 | 5.77 | 9.24 | 15.43 | -3.09 | |
| ROCE Annual % | 8.17 | 7.37 | 7.57 | 8.31 | 3.36 | |
| Total Debt to Total Equity Annual | 0.08 | 0.09 | 0.10 | 0.13 | 0.49 | |
| EBDIT Annual Margin % | 11.83 | 12.69 | 11.76 | 13.39 | 13.59 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Pawan Chaudhary | 12.82 | 74203343 | 0 | 35.01 |
| Manu Chaudhary | 11.73 | 74203344 | 0 | 27.1 |
| Sunev Pharma Solutions Limited | 17.21 | 74203349 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| Acadian Emerging Markets Micro-Cap Equity Master Fund | 1.05 | 74203353 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| K.B.Shekar | 1.97 | 74203371 |
| HUF | 2.67 | 74203355 |
| Mc Jain Infoservices Private Limited | 1.28 | 74203368 |
| Pradeep Kumar Jain | 1.19 | 74203373 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 23, 2013 | 3 | FINAL | - | Equity Share |
| Sep 20, 2012 | 3 | FINAL | - | Equity Share |
| Sep 22, 2011 | 3 | FINAL | - | Equity Share |
| Sep 23, 2010 | 3 | FINAL | - | Equity Share |
| Sep 17, 2009 | 3 | FINAL | - | Equity Share |
| Sep 12, 2008 | 4 | FINAL | - | Equity Share |
| Sep 18, 2007 | 3 | FINAL | - | Equity Share |
| Sep 21, 2006 | 2 | FINAL | - | Equity Share |
| Feb 03, 2005 | 1 | INTERIM | Feb 04, 2005 | Equity Share |
| Sep 11, 2002 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 30, 2024 | Audited Results | - |
| Feb 14, 2024 | Quarterly Results | - |
| Nov 09, 2023 | Quarterly Results | - |
| Aug 14, 2023 | Quarterly Results | - |
| Jul 14, 2023 | Others | - |
| May 29, 2023 | Audited Results | - |
| Jan 30, 2023 | Quarterly Results | - |
| Nov 12, 2022 | Quarterly Results | - |
| Jul 30, 2022 | Quarterly Results | - |
| May 27, 2022 | Audited Results | - |
| Jan 31, 2022 | Quarterly Results | - |
| Dec 30, 2021 | Others | Inter alia, to consider the appointment of additional director Independent director. |
| Oct 30, 2021 | Quarterly Results | - |
| Aug 12, 2021 | Quarterly Results & A.G.M. | - |
| May 31, 2021 | Audited Results & Preferential issue | - |
| Feb 23, 2021 | Others | Inter alia, to consider the allotment of 10,25,000 warrants fully convertible into equity shares to promoters of the company on preferential basis. |
| Feb 08, 2021 | Quarterly Results | - |
| Jan 15, 2021 | Others | Inter alia, 1. Finalization of date, time of Extra Ordinary General Meeting (EGM) of the Company. 2. To consider and approve draft Notice of EGM |
| Nov 06, 2020 | Quarterly Results & A.G.M. | - |
| Sep 15, 2020 | Quarterly Results | - |
| Aug 21, 2020 | Audited Results | (Revised) |
| Jul 31, 2020 | Audited Results | - |
| Feb 12, 2020 | Quarterly Results | - |
| Nov 12, 2019 | Quarterly Results | - |
| Aug 13, 2019 | Quarterly Results & Others | inter alia, approved the following: 1.To take note on appointment of Mr. Brij Mohan Sharma as Additional Director 2.Re-appointment of Mr. Chaudhary as Managing Director of the Company. |
| May 29, 2019 | Audited Results | - |
| Feb 14, 2019 | Quarterly Results | - |
| Nov 14, 2018 | Quarterly Results | - |
| Aug 13, 2018 | Quarterly Results & A.G.M. | - |
| May 28, 2018 | Audited Results | - |
| Feb 12, 2018 | Quarterly Results | - |
| Jan 10, 2018 | Others | - |
| Jan 08, 2018 | Others | To consider and approve: 1) To approve date of opening and closing of QIP issue. 2) To approve Preliminary Placement Document for QIP issue. 3) To decide the Floor price and Issue price for QIP issue. |
| Dec 07, 2017 | Quarterly Results | - |
| Sep 01, 2017 | Others | (Revised) |
| Aug 25, 2017 | Quarterly Results | - |
| Aug 03, 2017 | Others | - |
| May 30, 2017 | Audited Results | - |
| Apr 13, 2017 | Others | To inter alia appoint statutory auditor under section 139 of the Companies Act, 2013 and any other item with the permission of chair. |
| Apr 01, 2017 | Others | Appointed M/s Prem Garg & Associates, Chartered Accountants as statutory auditors of the Company. |
| Mar 18, 2017 | Others | To Preferential issueo inter alia allot 9,00,000 equity shares on conversion of fully convertible warrants to Promoters on preferential basis and any other item with the permission of chair. |
| Feb 22, 2017 | Raising of funds | To consider and approve raising of funds by way of Qualified Institutional Placement (QIP). |
| Feb 08, 2017 | Quarterly Results & Others | To allot warrants/equity shares to promoters of the Company on preferential basis. |
| Nov 09, 2016 | Quarterly Results | - |
| Aug 06, 2016 | Quarterly Results & Others | To issue fully convertible warrants/equity shares to promoters on a preferential basis subject to approval in the general meeting. |
| Jun 24, 2016 | Others | To consider the status of preferential issue of shares which was passed at last AGM, which is still pending for implementation. |
| May 28, 2016 | Audited Results | - |
| Feb 10, 2016 | Quarterly Results | - |
| Dec 19, 2015 | Others | To reconsider the relevant date for the preferential issue approved by the shareholders in AGM dated August 25, 2015. |
| Nov 13, 2015 | Quarterly Results | - |
| Aug 14, 2015 | Quarterly Results | - |
| Jun 30, 2015 | Issue of Securities & Others | 1. To issue fully convertible warrants/equity shares to promoters on a preferential basis subject to approval in the general meeting. 2. To Fix the date of Annual General Meeting. |
| Feb 13, 2015 | Quarterly Results | - |
| Nov 14, 2014 | Quarterly Results | To fix date of Annual General Meeting. |
| Aug 13, 2014 | Quarterly Results | - |
| May 30, 2014 | Audited Results | - |
| Feb 12, 2014 | Quarterly Results | - |
| Nov 11, 2013 | Quarterly Results | - |
| Aug 03, 2013 | Quarterly Results | - |
| May 18, 2013 | To consider raising of funds | - |
| Feb 07, 2013 | Quarterly Results | - |
| Nov 03, 2012 | Quarterly Results | - |
| Aug 04, 2012 | Quarterly Results | - |
| Jun 21, 2012 | Audited Results & Dividend | - |
| May 04, 2012 | Quarterly Results | - |
| Feb 27, 2012 | Issue & Allotment of Equity Shares | The Board has approved allotment of 600,000 Equity Shares of Rs. 10/- each to Promoter Group Company pursuant to conversion of Warrants Fully Convertible into Equity Shares. |
| Jan 27, 2012 | Quarterly Results | - |
| Dec 21, 2011 | Allotment of Warrants | Inter alia, to consider allotment of 17,00,000 Warrants Fully Convertible into Equity Shares to Promoter Group Company on a preferential basis. |
| Oct 31, 2011 | Quarterly Results | - |
| Aug 24, 2011 | Allotment of Equity Shares & Others | - |
| Jul 26, 2011 | Audited, Quarterly Results & Dividend | - |
| Apr 30, 2011 | Quarterly Results | - |
| Mar 30, 2011 | Allotment of Equity Shares | Inter alia, to consider and approve allotment of 6,00,000 Equity Shares of Rs. 10 each to Promoter group Company pursuant to Conversion of Warrants Fully Convertible into Equity Shares. |
| Jan 28, 2011 | Quarterly Results | - |
| Dec 18, 2010 | Allotment of Equity Shares | To consider allotment of 37,137 equity shares pursuant to request for partly conversion of Foreign Currency Convertible Bonds by FCCB holders, out 5 million bonds rollover till 2015. |
| Oct 15, 2010 | Quarterly Results & Others | - |
| Aug 24, 2010 | Preferential Allotment of Warrants | To issue upto 12,00,000 Warrants of Rs. 10/- each at such price as determined as per the SEBI rules & regulations on preferential allotment basis to Sunev Pharma Solutions Ltd., a promoter group Co. |
| Jul 31, 2010 | Audited, Quarterly Results & Dividend | - |
| Apr 24, 2010 | Quarterly Results & ESOP | The Board has allotted 18866 Equity Shares under ESOP Scheme. |
| Jan 16, 2010 | Quarterly Results | - |
| Oct 31, 2009 | Quarterly Results | - |
| Aug 21, 2009 | Audited Results & Dividend | - |
| Jul 30, 2009 | Quarterly Results | - |
| Apr 30, 2009 | Quarterly Results & ESOP | inter alia, to approve the allotment of 19,868 equity shares of Rs 10/- each cash at par under Employees Stock Options Scheme pursuant to exercise of options. (Revised) |
| Jan 31, 2009 | Quarterly Results | - |
| Oct 30, 2008 | Quarterly Results | - |
| Jul 29, 2008 | Audited, Qtr Results & Dividend | To change of Registered Office within the same city and to fix the date of Annual General Meeting. |
| Apr 29, 2008 | Quarterly Results | - |
| Jan 28, 2008 | Quarterly Results & ESOP | - |
| Oct 22, 2007 | Quarterly Results | - |
| Aug 20, 2007 | Audited Results & Dividend | - |
| Jul 23, 2007 | Quarterly Results | - |
| Apr 25, 2007 | Quarterly Results & ESOP | - |
| Feb 06, 2007 | Others | Inter alia, to consider enhancing the limit of FII's and NRI's in paid up equity capital of the Company. |
| Jan 15, 2007 | Quarterly Results | - |
| Oct 16, 2006 | Quarterly Results | - |
| Aug 19, 2006 | Accounts & Dividend | - |
| Jul 17, 2006 | Quarterly Results | - |
| Apr 28, 2006 | Allotment of FCCB's | To allot Foreign Currency Convertible Bonds ("FCCBs") for US$ 12 million. Out of this Bonds for US$ 2 million are pursuant to exercise of Green Shoe Option. |
| Apr 15, 2006 | Quarterly Results & Others | Proposed to consider the terms of GDR / FCCB, offer opening date and finalization of various agencies pertaining to issue. |
| Mar 16, 2006 | To consider issue of FCCB's | To consider inter alia issue of FCCB and calling of EGM. |
| Jan 16, 2006 | Quarterly Results | - |
| Dec 11, 2005 | Appointment of Directors | - |
| Oct 10, 2005 | Quarterly Results | - |
| Oct 01, 2005 | Employees Stock Option Plan | - |
| Aug 20, 2005 | Accounts & ESOP | - |
| Jul 11, 2005 | Quarterly Results | - |
| Jun 15, 2005 | Allotment of shares | To consider allotment of 20,00,000 shares @ Rs 10/- each pursuant to exercising of option of conversion of Zero Coupon Optionally Convertible Warrants. |
| Apr 18, 2005 | Quarterly Results | - |
| Jan 20, 2005 | Quarterly Results & Interim Dividend | - |
| Oct 18, 2004 | Quarterly Results | - |
| Sep 09, 2004 | Preferential Issue of shares | to promoters. |
| Aug 28, 2004 | Accounts & Others | Voluntary Delisting of Shares |
| Jul 27, 2004 | Quarterly Results | - |
| Apr 20, 2004 | Quarterly Results | - |
| Jan 15, 2004 | Quarterly Results | - |
| Dec 20, 2003 | Preferential Issue of shares | to promoters. (Revised) |
| Oct 15, 2003 | Preferential Issue of shares | Preferential Issue of shares to promoters, issue of warrants to persons other than existing shareholders. |
| Aug 26, 2003 | Accounts & Others | Preferential Issue of shares to promoters |
| Jul 31, 2003 | Quarterly Results | - |
| Apr 30, 2003 | Quarterly Results | - |
| Jan 31, 2003 | Quarterly Results | - |
| Oct 31, 2002 | Unaudited Financial Results | - |
| Aug 24, 2002 | Accounts | - |
| Apr 30, 2002 | Quarterly Results | - |
| Jan 31, 2002 | Quarterly Results | - |
| Aug 20, 2001 | Accounts | - |
| Apr 30, 2001 | Unaudited Financial Results | - |
| Jan 31, 2001 | Quarterly Results | - |
| Oct 31, 2000 | Quarterly Results | - |
| Aug 05, 2000 | Accounts | - |
| Jul 31, 2000 | Quarterly Results | - |
| Apr 29, 2000 | Quarterly Results | - |
| Mar 01, 2000 | Preferential Offer | - |
| Jan 31, 2000 | Quarterly Results | - |
| Oct 31, 1999 | Quarterly Results | - |
| Jul 31, 1999 | Quarterly Results | - |
| Jul 30, 1998 | Quarterly Results & Pref. Offer | - |
| May 30, 1998 | Half Yearly Results | - |
| Nov 29, 1997 | Half Yearly Results | - |
| May 31, 1997 | Half Yearly Results. | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
29 Jun 2024
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under reg 39(3) for stop transfer.
20 Jun 2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Clinches WHO-Backed PAHO Tender, Takes Its Global Fight Against Cancer To Next Level
Venus Remedies Clinches WHO-backed PAHO Tender.
13 Jun 2024
Venus Remedies up 8% on order win from UNICEF for bacterial infection drug
The uptick in stock price came after the company announced that it has secured an award for its antibiotic product, Ceftriaxone 1 gm, from UNICEF
13 Jun 2024
VENUS REMEDIES LTD. - 526953 - Venus Remedies Achieves Major Milestone With UNICEF
Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product.
01 Jun 2024
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of financial results as on 31st March 2024
30 May 2024
VENUS REMEDIES LTD. - 526953 - Financial Results As On 31.03.2024.
Financial results as on 31.03.2024
30 May 2024
VENUS REMEDIES LTD. - 526953 - Board Meeting Outcome for Outcome Of Board Meeting Dated 30.05.2024
1. Audited Financial Results for the quarter and year ended on 31st March 2024 along with Audit report. 2. Amended the Code of conduct to regulate, monitor and reporting of trading by designated persons/insiders and Code of practices and procedures for fair disclosure of unpublished price sensitive information, both are available on Company website-www.venusremedies.com.
22 May 2024
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Stop Transfer intimation.
18 May 2024
VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Board Meeting Scheduled To Be Held On 30Th May 2024.
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 ,inter alia, to consider and approve 1. Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March 2024. 2. Any other business with the permission of Chair.
